Gossamer Bio, Inc. · NASDAQ:GOSS
Gossamer Bio — Q1 2026 Earnings Presentation
21 slides from Gossamer Bio's earnings presentation, May 18, 2026
Slide 1: 1Q26 Earnings Update
1Q26 Earnings Update May 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategies and plans, research a
Slide 3: Speakers on Today's Call
Speakers on Today’s Call • Faheem Hasnain, Co-Founder, Chairman & Chief Executive Officer • Bryan Giraudo, Chief Operating Officer & Chief Financial Officer • Bob Smith, Chief Commercial Officer • Caryn Peterson, Executive Vice President, Regulatory Affairs • Dr. Rob Roscigno, Senior Vice President,
Slide 4: I. Regulatory Update
|. Regulatory Update gossamerbio
Slide 5: In-Person FDA Type B Meeting Confirmed for Mid-June
In-Person FDA Type B Meeting Confirmed for Mid-June • FDA has confirmed an in-person meeting for Mid-June • Meeting will address the regulatory path forward for seralutinib, including discussion of the totality of clinical evidence across the clinical program • Subject to a productive Type B meeting
Slide 6: II. PROSERA CT FRI Substudy Topline Results
II. PROSERA CT FRI Substudy Topline Results
Slide 7: PROSERA CT FRI Substudy: Most Comprehensive Controlled Vascular Imaging Dataset in PAH to Date
PROSERA CT FRI Substudy: Most Comprehensive Controlled Vascular Imaging Dataset in PAH to Date • Clinical endpoints show whether patients improved; computed tomography functional respiratory imaging (CT FRI) reveals the anatomical basis of that improvement, which is key for a non-vasodilator • Built
Slide 8: Seralutinib Demonstrated Multi-Compartment Vascular Effects
Seralutinib Demonstrated Multi-Compartment Vascular Effects Seralutinib Patient Case Study: • Prespecified imaging endpoints showed statistically significant, multi- Visualization of Reverse Remodeling compartment effects of seralutinib across arterial, venous, and fibrosis- Baseline like parenchyma
Slide 9: PAH Is a Multi-Compartment Vascular Disease, Not Just Arterial Remodeling
PAH Is a Multi-Compartment Vascular Disease, Not Just Arterial Remodeling • PAH is a multi-compartment disease Pulmonary Arteries Capillary Bed Pulmonary Veins including: • Arterial remodeling • Capillary dropout • Venous underfilling Deoxygenated Blood Flow Gas Exchange Oxygenated Blood Flow • Peri
Slide 10: Seralutinib is Designed to Act Across Arteries, Veins, and Lung Parenchyma
Seralutinib is Designed to Act Across Arteries, Veins, and Lung Parenchyma Pulmonary Arteries Parenchymal Space Pulmonary Veins PDGFRα/β PDGFRα/β (fibroblasts) → + CSF1R (macrophages) Upstream arterial remodeling + anti-fibrotic PASMC proliferation + c-KIT (mast cells) effects PAH → → (incl. sub-CT
Slide 11: Seralutinib Showed Reversed Proximal Arterial Remodeling
Seralutinib Showed Reversed Proximal Arterial Remodeling • Seralutinib significantly decreased large arterial blood volume Seralutinib Decreased BV10A% proportion (BV10A%) v. placebo, indicating of proximal arterial decompression • Consistent with TORREY arterial results, now reproduced in a much la
Slide 12: Seralutinib Reduces Fibrosis-Like Parenchymal Features While Placebo Increases
Seralutinib Reduces Fibrosis-Like Parenchymal Features While Placebo Increases • Seralutinib significantly decreased functional respiratory imaging (FRI) fibrosis metrics (1), placebo increased Seralutinib Decreased Fibrosis-like Volume Metric • First demonstration of statistically significant fibro
Slide 13: First Evidence of Venous Vascular Recovery in a Controlled PAH Trial
First Evidence of Venous Vascular Recovery in a Controlled PAH Trial • In the PROSERA substudy, seralutinib significantly increased venous blood volume; placebo decreased • Consistent increases across venous vessel sizes and vascular branching (fractal dimension), suggesting improved microvascular f
Slide 14: Functional Respiratory Imaging (FRI) Links Vascular Structure to Clinical Trajectory in PAH
Functional Respiratory Imaging (FRI) Links Vascular Structure to Clinical Trajectory in PAH • At baseline, arterial, venous, and vascular complexity parameters correlated with pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (mPAP), cardiac output, and clinical outcome measures
Slide 15: Seralutinib Demonstrated Statistically Significant Treatment Effects Across Multiple Vascular Compartments
Seralutinib Demonstrated Statistically Significant Treatment Effects Across Multiple Vascular Compartments Category Parameter Abbrev. Effect p-value Interpretation Arterial Arterial vessel volume >10mm² / TBV BV10A% ↓ Decrease 0.020* Reduced proportion of large-artery volume consistent with
Slide 16: Two Patients on Triple Background Therapy, Two Trajectories
Two Patients on Triple Background Therapy, Two Trajectories: Visualization of Reverse Remodeling (Placebo v. Seralutinib) Placebo patient Seralutinib patient Baseline Week 24 Baseline Week 24 60y Female, PAH-CTD, FC 3, Triple Therapy 70y Female, IPAH, FC 3, Triple Therapy Δ 6MWD -1 m Δ 6MWD +55 m Δ
Slide 17: Visible Reduction in Fibrosis-like Parenchymal Features Seen in PAH Patient
Visible Reduction in Fibrosis-like Parenchymal Features Seen in PAH Patient Baseline Week 24 • Fibrosis volume (FV) quantified via FibroNet, a deep-learning algorithm trained on confirmed idiopathic pulmonary fibrosis (IPF) data (analogous to High Attenuation Abnormalities [HAA] in ILD imaging) • CT
Slide 18: Why Does It Matter?
Why Does It Matter? • Multi-compartment vascular and parenchymal remodeling effects of this breadth have not been shown by traditional vasodilator therapies • First controlled-trial imaging evidence of arterial decompression with concomitant venous vascular expansion, indicating coordinated restorat
Slide 19: III. Bond Exchange
Ill. Bond Exchange gossamerbio
Slide 20: Addressing the Capital Structure
Addressing the Capital Structure Existing Notes $200mm, 5.00% Convertible Senior Notes due 2027 Per $1,000 principal: up to 1,588.2353 shares of common stock (or pre-funded warrants in lieu Exchange Consideration thereof) + $360 principal amount of new secured notes + 750 early tender purchase warra
Slide 21: Thank you
Thank you gossamerbio 21